Cytomedix Announces Collaboration With Duke University on Phase I Clinical Study of ALD-451 in Malignant Glioma

Regenerative therapies company Cytomedix announced the initiation of a Phase 1 clinical study in brain cancer patients in collaboration with Duke University Medical Center.... [more]

View complete Press Release article